1 completed, 1 unknown, 1 withdrawn. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma Ixazomib, Pomalidomide, Lenalidomide - Multiple Myeloma | Phase 4 | Withdrawn | Takeda | 2022-06-30 | 2022-05-03 | |
| Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5., Placebo - COVID-19 | Phase 4 | Unknown | Hospital Universitario Getafe | 120 | 2020-10-27 | 2020-07-31 |
| Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Completed | Columbia University | 60 | 2012-09-01 | 2020-02-05 |
Multiple Myeloma (2) · COVID-19 (1)
Columbia University (1) · Hospital Universitario Getafe (1) · Takeda (1)
Spain (1) · United States (1)
Joaquin De Haro, MD (1) · Suzanne Lentzsch, MD (1)